The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

Abstract Background Recently, a series of clinical trials showed that combination of anti-programmed cell death-1 (α-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (α-CTLA-4) could effectively eliminate tumor. However, in comparison with widely adopted mono-immune checkpoint inhibitors,...

Full description

Bibliographic Details
Main Authors: Kongju Wu, Ming Yi, Shuang Qin, Qian Chu, Xinhua Zheng, Kongming Wu
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Experimental Hematology & Oncology
Subjects:
Immunotherapy
PD-1
PD-L1
CTLA-4
Immune checkpoint inhibitor
Combination therapy
Online Access:http://link.springer.com/article/10.1186/s40164-019-0150-0

Similar Items

Similar Items